Гиперпролактинемия в акушерско-гинекологической практике

1. Мельниченко Г.А., Дзеранова Л.К., Пигарова Е.А., Воротникова С.Ю., Рожинская Л.Я., Дедов И.И. Федеральные клинические рекомендации по клинике, диагностике, дифференциальной диагностике и методам лечения гиперпролактинемии. Проблемы эндокринологии. 2013; 59(6): 19-26.

2. Melmed S., Casanueva F.F., Hoffman A.R., Kleinberg D.L., Montori V.M., Schlechte J.A. et al. Diagnosis and treatment of hyperprolactinemia: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 2011; 96(2): 273-88. doi: 10.1210/jc.2010-1692.

3. Дедов И.И., Мельниченко Г.А., ред. Рациональная фармакотерапия заболеваний эндокринной системы и нарушений обмена веществ. 2-е изд. М.: Литтерра; 2013. 1024с.

4. Дедов И.И., Мельниченко Г.А., ред. Эндокринология. Национальное руководство. 2-е изд. М.: ГЭОТАР-Медиа; 2016. 1112с.

5. Capozzi A., Scambia G., Pontecorvi A., Lello S. Hyperprolactinemia: pathophysiology and therapeutic approach. Gynecol. Endocrinol. 2015; 31(7): 506-10.

6. Whyte M.B., Pramodh S., Srikugan L., Gilbert J.A., Miell J.P., Sherwood R.A. et al. Importance of cannulated prolactin test in the definition of hyperprolactinaemia. Pituitary. 2015; 18(3): 319-25. doi: 10.1007/s11102-014-0576-7.

7. Maiter D., Primeau V. Update in the treatment of prolactinomas. Ann. Endocrinol. (Paris). 2012; 73(2): 90-8. doi: 10.1016/j.ando.2012.03.024.

8. De Hert M., Detraux J., Peuskens J. Second-generation and newly approved antipsychotics, serum prolactin levels and sexual dysfunctions: a critical literature review. Expert Opin. Drug Saf. 2014;13(5): 605-24.

9. Samson S.L., Hamrahian A.H., Ezzat S.; AACE Neuroendocrine and Pituitary Scientific Committee; American College of Endocrinology (ACE). American Association of Clinical Endocrinologists, American College of Endocrinology disease state clinical review: clinical relevance of macroprolactin in the absence or presence of true hyperprolactinemia. Endocr. Pract. 2015; 21(12): 1427-35. doi: 10.4158/EP15938.DSC.

10. Kars M., Souverein P.C., Herings R.M., Romijn J.A., Vandenbroucke J.P., de Boer A., Dekkers O.M. Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia. J. Clin. Endocrinol. Metab. 2009; 94(8): 2729-34. doi: 10.1210/jc.2009-0177.

11. Dos Santos Nunes V., El Dib R., Boguszewski C.L., Nogueira C.R. Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis. Pituitary. 2011; 14(3): 259-65. doi: 10.1007/s11102-010-0290-z.

12. Wang A.T., Mullan R.J., Lane M.A., Hazem A., Prasad C., Gathaiya N.W. et al. Treatment of hyperprolactinemia: a systematic review and meta-analysis. Syst. Rev. 2012; 1: 33. doi: 10.1186/2046-4053-1-33.

13. Glezer A., Bronstein M.D. Prolactinomas, cabergoline, and pregnancy. Endocrine. 2014; 47(1): 64-9. doi: 10.1007/s12020-014-0334-7.

14. Auriemma R.S., Perone Y., Di Sarno A., Grasso L.F., Guerra E., Gasperi M. et al. Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation. J. Clin. Endocrinol. Metab. 2013; 98(1): 372-9.

15. Rastogi A., Bhadada S.K., Bhansali A. Pregnancy and tumor outcomes in infertile women with macroprolactinoma on cabergoline therapy. Gynecol. Endocrinol. 2016; Dec 2: 1-4. doi: 10.1080/09513590.2016.1254177.

16. Hu J., Zheng X., Zhang W., Yang H. Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis. Pituitary. 2015; 18(5): 745-51. doi: 10.1007/s11102-014-0617-2.

17. D’Sylva C., Khan T., Van Uum S., Fraser L.A. Osteoporotic fractures in patients with untreated hyperprolactinemia vs. those taking dopamine agonists: A systematic review and meta-analysis. Neuroendocrinol. Lett. 2015; 36(8):745-9.

18. Medic-Stojanoska M., Icin T., Pletikosic I., Bajkin I., Novakovic-Paro J., Stokic E. et al. Risk factors for accelerated atherosclerosis in young women with hyperprolactinemia. Med. Hypotheses. 2015; 84(4): 321-6. doi: 10.1016/j.mehy.2015.01.024.

19. Krysiak R., Okopien B. Different effects of cabergoline and bromocriptine on metabolic and cardiovascular risk factors in patients with elevated prolactin levels. Basic Clin. Pharmacol. Toxicol. 2015; 116(3): 251-6. doi: 10.1111/bcpt.12307.

20. Bolanowski M., Zadrozna-Sliwka B., Jawiarczyk A., Syrycka J. The influence of other than prolactin hormones on bone mineral density in women with hyperprolactinaemia of various origins. Gynecol. Endocrinol. 2010; 26(8): 623-7. doi: 10.3109/09513591003686320.

21. Mazziotti G., Mancini T., Mormando M., De Menis E., Bianchi A., Doga M. et al. High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas. Pituitary. 2011; 14(4): 299-306. doi: 10.1007/s11102-011-0293-4.

22. dos Santos Silva C.M., Barbosa F.R., Lima G.A., Warszawski L., Fontes R., Domingues R.C. et al. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity (Silver Spring). 2011; 19(4): 800-5. doi: 10.1038/oby.2010.150.

Поступила 07.02.2017

Принята в печать 17.02.2017